Trial Profile

A Phase 3 double-blind, placebo-controlled study clinical trial to determine effect of enobosarm in older (> 60 years) age patients who have obesity or who are overweight and who are eligible for treatment with GLP-1 RA (semaglutide and/or tirzepatide)

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 10 Oct 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Aug 2025 According to a Veru media release, the Company has been granted an FDA meeting to discuss its Phase 3 program.
03 Feb 2025 New trial record
27 Jan 2025 According to a Veru media release, company is planning to meet FDA, to discuss regulatory path and the design of anticipated Phase 3 clinical program.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com